News >

Emerging Developments in CML

Jonathan Alicea and Gina Columbus
Published: Saturday, Jul 29, 2017

Kendra Sweet, MD

Kendra Sweet, MD
Appropriate and effective first-line therapies for patients with newly diagnosed chronic myeloid leukemia (CML) are currently under investigation. Groundbreaking clinical trials involving tyrosine kinase inhibitors (TKIs), such as imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna), show promising results in the treatment of patients with CML, explains Kendra Sweet, MD.

on Hematologic Malignancies, Sweet discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.

OncLive: Can you give an overview of the main points discussed in your presentation?

Sweet: One of the main points I brought up in my presentation was selection of firstline therapy for a newly diagnosed patient with CML. What are the factors that need to be considered when making the decision on how to appropriately treat someone in the upfront setting? We’re looking at things like risks scores, comorbidities, and longterm goals, and then analyzing the data from all frontline studies to make a decision about how to best treat those patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x